How it works?

Predictive biomarkers in gastroesophageal adenocarcinoma: tips and tricks

Prof. Matteo Fassan


Recent molecular data obtained on gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted treatments in the current clinical practice. As a result, several biomarkers have been introduced into histopathology routine practice and such assessments are mainly based on the evaluation of limited endoscopy biopsy material. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.


Diapath Lab Talks | Privacy Policy